BioCentury | Aug 3, 2018
Finance

Lin’s new chapters

...through Phase II testing if needed. Lin indicated that, despite a 2014 slump in the Taiwan biotech...
BioCentury | May 11, 2018
Finance

Aslan’s insiders

...NT$992 million ($33 million) in its May 2017 IPO on the Taipei Exchange. But the Taiwan biotech...
BioCentury | Dec 22, 2017
Financial News

JHL delisting from TPEx

...including a potential listing on another exchange. JHL was viewed as a potential bellwether for Taiwan biotech...
BioCentury | Dec 21, 2017
Financial News

JHL delisting from TPEx

...Inc. executives, Racho Jordanov and Rose Lin, JHL was viewed as a potential bellwether for Taiwan biotech...
BioCentury | Sep 21, 2015
Finance

Hedging in Asia

Ally Bridge Group expects its newest investment vehicle - an Asia-focused healthcare hedge fund - will have a surplus of buying opportunities given the plunge of the stock market in China. In other territories, such as Taiwan,...
BioCentury | Aug 3, 2015
Finance

Taiwan's post-bubble prognosis

...in Taiwan's technology and IT plays has come at biotech's expense. The meteoric rise of Taiwan biotech...
...down. That news was followed this spring by a report of clinical data by another Taiwan biotech...
BioCentury | Feb 23, 2015
Finance

Daiwa dives in

The Daiwa Corporate Investment Co. Ltd. private equity arm of Daiwa Securities Group has for years made one-off investments in biotechs from its general funds. But the group decided a favorable investment climate for biotechs...
BioCentury | Jan 1, 2015
Top Story

Taiwan, China embark on cross-strait clinical studies

...it will surely expedite the clinical trial execution process, which will create another benefit for Taiwan biotech...
...structure infections (ABSSSIs). TaiGen has exclusive, worldwide rights to Taigexyn from Actavis plc (NYSE:ACT). The Taiwan biotech...
BioCentury | Nov 10, 2014
Clinical News

ADXS-HPV: Preliminary Phase I/II data

...II-IV invasive cervical cancer, HPV-associated anal cancer and HPV-associated head and neck cancer. Last year, Taiwan Biotech Co. Ltd....
BioCentury | Sep 1, 2014
Company News

University of Pennsylvania, Advaxis deal

...II-IV invasive cervical cancer, HPV-associated anal cancer and HPV-associated head and neck cancer. In December, Taiwan Biotech Co. Ltd....
Items per page:
1 - 10 of 17
BioCentury | Aug 3, 2018
Finance

Lin’s new chapters

...through Phase II testing if needed. Lin indicated that, despite a 2014 slump in the Taiwan biotech...
BioCentury | May 11, 2018
Finance

Aslan’s insiders

...NT$992 million ($33 million) in its May 2017 IPO on the Taipei Exchange. But the Taiwan biotech...
BioCentury | Dec 22, 2017
Financial News

JHL delisting from TPEx

...including a potential listing on another exchange. JHL was viewed as a potential bellwether for Taiwan biotech...
BioCentury | Dec 21, 2017
Financial News

JHL delisting from TPEx

...Inc. executives, Racho Jordanov and Rose Lin, JHL was viewed as a potential bellwether for Taiwan biotech...
BioCentury | Sep 21, 2015
Finance

Hedging in Asia

Ally Bridge Group expects its newest investment vehicle - an Asia-focused healthcare hedge fund - will have a surplus of buying opportunities given the plunge of the stock market in China. In other territories, such as Taiwan,...
BioCentury | Aug 3, 2015
Finance

Taiwan's post-bubble prognosis

...in Taiwan's technology and IT plays has come at biotech's expense. The meteoric rise of Taiwan biotech...
...down. That news was followed this spring by a report of clinical data by another Taiwan biotech...
BioCentury | Feb 23, 2015
Finance

Daiwa dives in

The Daiwa Corporate Investment Co. Ltd. private equity arm of Daiwa Securities Group has for years made one-off investments in biotechs from its general funds. But the group decided a favorable investment climate for biotechs...
BioCentury | Jan 1, 2015
Top Story

Taiwan, China embark on cross-strait clinical studies

...it will surely expedite the clinical trial execution process, which will create another benefit for Taiwan biotech...
...structure infections (ABSSSIs). TaiGen has exclusive, worldwide rights to Taigexyn from Actavis plc (NYSE:ACT). The Taiwan biotech...
BioCentury | Nov 10, 2014
Clinical News

ADXS-HPV: Preliminary Phase I/II data

...II-IV invasive cervical cancer, HPV-associated anal cancer and HPV-associated head and neck cancer. Last year, Taiwan Biotech Co. Ltd....
BioCentury | Sep 1, 2014
Company News

University of Pennsylvania, Advaxis deal

...II-IV invasive cervical cancer, HPV-associated anal cancer and HPV-associated head and neck cancer. In December, Taiwan Biotech Co. Ltd....
Items per page:
1 - 10 of 17